NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. This shipment is significant because it makes the drug locally available for potential use in response efforts against MPox and other viral outbreaks. NanoViricides noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections.
The implications of this announcement are far-reaching. MPox, particularly the Clade I strain, poses a serious public health threat in the DRC and neighboring regions. If NV-387 proves safe and effective in this Phase II trial, it could become a critical treatment option not only for MPox but also for other viral diseases such as Ebola. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
NV-387 is the company's lead drug candidate, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPox/smallpox and even measles. The drug's mechanism of action involves polymeric micelles that target viruses directly, potentially offering a novel approach to antiviral therapy. The company has also developed NV-CoV-2-R, which encapsulates remdesivir within NV-387's polymeric micelles, and believes this candidate could be approvable given remdesivir's existing FDA approval.
The DRC trial represents a critical step for NanoViricides as it transitions from preclinical to clinical development. The company's ability to enroll patients and gather data on safety and efficacy will be closely watched by investors and public health officials. If successful, NV-387 could address unmet medical needs in regions where viral outbreaks are common and treatment options are limited.
Beyond MPox, NanoViricides is developing drugs against a range of viral diseases, including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola. The company's platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc., and holds exclusive perpetual licenses for several viral targets.
The news of the shipment to the DRC underscores NanoViricides' commitment to advancing its clinical pipeline. For more information, the full press release is available at https://ibn.fm/CTIZc. Updates on the company are also available in its newsroom at https://ibn.fm/NNVC.
